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Personalized cancer care depends substantially on three
key elements i) modern interventions by surgery, radiation
and therapeutics, ii) predictive diagnostics for each inter-
vention, iii) predictive data models and mathematics that
integrate each time point of each patient into larger popu-
lations. Patients with solid tumors have suffered particu-
larly from the absence of routine access to relevant tumor
tissue and precision diagnostics that predict response to
therapy. Similarities can be drawn to the conversion of
HIV from a deadly disease to a chronic condition through
the ability to accurately understand the current viral load
and prescribe the relevant drug cocktail. This same con-
cept is now being followed in carcinomas by utilizing a
simple blood sample as a fluid biopsy to extract individual
cancer cells and conduct high-content single cell analysis
for the development of predictive biomarkers.
The fluid phase of solid tumors is a clinical tool in per-
sonalized cancer care and an emerging research tool in
basic science cancer discoveries. Utilizing the HD-CTC
assay, we are undertaking a series of clinical studies inves-
tigating the metastatic pathways in cancer patients. The
fluid phase of solid tumors is a critical third microenviron-
ment in the development and progression of carcinomas.
Cells originating from primary or secondary sites travel
through the blood circulatory system to either get cleared
out or initiate new tumor growth. Translational research
efforts are attempting to identify the various subtypes of
circulating tumor cells (CTCs), their origins, their destina-
tions and their impact on the disease. Understanding and
characterizing CTCs is a first step towards utilizing them
as both biopsy material and directly as a biomarker.
It requires approaches of subtyping CTCs at the single cell
level using molecular and cellular approaches. The
immediate use is the use of the HD-CTC assay as a fluid
biopsy for therapeutic stratification.
The success of the fluid biopsy in real-time stratification
of patient treatments will both improve patient outcomes
by enabling higher treatment success rates and radically
improve healthcare economics by reducing ineffective
treatments.
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